On 19 February, Cellectis S.A. (NASDAQ:CLLS) has appointed Mr. Eric Dutang as its Chief Financial Officer. Mr. Dutang also joins the Executive and Management Committees of Cellectis. Mr. Dutang succeeds Mr. Thierry Moulin.
Cellectis S.A. (NASDAQ:CLLS) belongs to Healthcare sector. Its net profit margin is -28.90% and weekly performance is -8.58%. On last trading day company shares ended up at $21.32. Cellectis S.A. (NASDAQ:CLLS) distance from 50-day simple moving average (SMA50) is 2.36%.
On 16 February, India Globalization Capital, Inc. (NYSEMKT:IGC) announces that it has acquired Cabaran Ultima, a 30 year old international project development company for a consideration of 998,571 shares of IGC common stock for a purchase price of $229,671.
India Globalization Capital, Inc. (NYSEMKT:IGC) shares increased 17.88% in last trading session and ended the day at $0.28. IGC Gross Margin is 8.00% and its return on assets is -17.80%. India Globalization Capital, Inc. (NYSEMKT:IGC) quarterly performance is 48.97%.
Oclaro, Inc. (NASDAQ:OCLR) announced that management is scheduled to participate in the Northland Capital Markets 2016 Growth Conference on March 9, 2016, in New York City.
On 24 February, Oclaro, Inc. (NASDAQ:OCLR) shares increased 3.43% and was closed at $4.82. OCLR EPS growth in last 5 year was -30.10%. Oclaro, Inc. (NASDAQ:OCLR) year to date (YTD) performance is 38.51%.
People’s United Financial, Inc. (NASDAQ:PBCT)‘s stock had its “hold” rating reaffirmed by Zacks Investment Research in a research report issued on Sunday, MarketBeat reports.
People’s United Financial Inc. (NASDAQ:PBCT) ended the last trading day at $14.56. Company weekly volatility is calculated as 2.17% and price to cash ratio as 4.40. People’s United Financial Inc. (NASDAQ:PBCT) showed a weekly performance of -0.82%.
Kite Pharma, Inc. (NASDAQ:KITE) announced the formation of the company’s integrated commercial leadership team with the appointment of three senior-level industry executives. The team will be responsible for all aspects of commercial and medical affairs strategy, planning, and analysis for the potential launch of KTE-C19, an investigational engineered T cell therapy for patients with relapsed and/or refractory B cell malignancies.
Kite Pharma, Inc. (NASDAQ:KITE) shares fell -0.97% in last trading session and ended the day at $44.97. KITE return on assets is -20.60%. Kite Pharma, Inc. (NASDAQ:KITE) quarterly performance is -45.77%.